A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

EVR and EPO for Liver Transplant Tolerance

NCT06832189 ·Status: RECRUITING ·Phase: PHASE1

Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant

NCT02429869 ·Status: COMPLETED ·Phase: PHASE4

Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.

NCT00170794 ·Status: COMPLETED ·Phase: PHASE3

A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients

NCT00369161 ·Status: COMPLETED ·Phase: PHASE4

This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.

NCT00531440 ·Status: COMPLETED ·Phase: PHASE3

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

NCT03955172 ·Status: RECRUITING ·Phase: NA

Everolimus in de Novo Heart Transplant Recipients

NCT01017029 ·Status: COMPLETED ·Phase: PHASE4

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

NCT01888432 ·Status: COMPLETED ·Phase: PHASE3

Shift to Everolimus (RAD) Kidney Sparing Study

NCT00420537 ·Status: TERMINATED ·Phase: PHASE4

Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients

NCT01551212 ·Status: COMPLETED ·Phase: PHASE4

Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus

NCT00134940 ·Status: COMPLETED

The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients

NCT02134899 ·Status: COMPLETED ·Phase: PHASE3

Novartis Everolimus Transition

NCT02096107 ·Status: COMPLETED ·Phase: PHASE4

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

NCT01404325 ·Status: COMPLETED ·Phase: PHASE3

The Everolimus-Transplant Exit Strategy Trial (E-TEST)

NCT01636466 ·Status: TERMINATED ·Phase: PHASE3

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

NCT01269684 ·Status: WITHDRAWN ·Phase: PHASE4

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

NCT02569125 ·Status: WITHDRAWN ·Phase: PHASE2

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

NCT00403416 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation

NCT02113891 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

NCT02040584 ·Status: COMPLETED ·Phase: PHASE3

Felzartamab in Late Antibody-Mediated Rejection

NCT05021484 ·Status: COMPLETED ·Phase: PHASE2

Everolimus in de Novo Kidney Transplant Recipients

NCT01410448 ·Status: COMPLETED ·Phase: PHASE3

24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients

NCT00555789 ·Status: TERMINATED ·Phase: PHASE2

Role of Everolimus in Highly Sensitized Patients

NCT01911546 ·Status: COMPLETED ·Phase: PHASE2